Centiva Capital, LP Allakos Inc. Call Options Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
Call Options
2 transactions
Others Institutions Holding ALLK
# of Institutions
81Shares Held
64.7MCall Options Held
47.1KPut Options Held
1K-
Bvf Inc San Francisco, CA16.6MShares$14.6 Million0.34% of portfolio
-
Nea Management Company, LLC Timonium, MD6.15MShares$5.41 Million0.31% of portfolio
-
Deep Track Capital, LP Greenwich, CT5MShares$4.4 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$3.09 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.08MShares$2.71 Million0.13% of portfolio
About Allakos Inc.
- Ticker ALLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 84,726,096
- Market Cap $74.6M
- Description
- Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...